Aurigene, Edity Introduce Cell Therapy Collaboration
The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.
Aurigene Pharmaceutical Services Limited, a contract research, development, and manufacturing services organization (CRDMO), will be offering discovery services to Edity Therapeutics Limited in the field of cell therapy.1
According to Edity—a company with various product candidates in the autoimmune disorders, gene therapy, oncology, and regenerative medicine spaces—it has designed a "first of its kind" immune cell delivery platform. As the description of the platform might suggest, it has the capability to deliver intracellular therapeutic proteins that target cells with accuracy. Edity decided to partner with Aurigene in order to support and quicken the clinical development of advanced and novel technologies, being that the CRDMO has a track record of success when it comes to advanced therapy discovery services.
"We are excited about the collaboration and look forward to working with Edity in building novel technologies,” said Akhil Ravi, CEO, Aurigene. “Edity’s cellular reprogramming technology to deliver therapeutic payloads, specifically to target cells, adds a new mechanism to CAR-T based cell therapeutics with the potential to significantly increase the efficacy."
When it comes to assisting pharma and biotech companies achieve accelerated development timelines and cost-effective manufacturing for biologics and small molecules, Aurigene has two decades of experience in this area. Biologics-wise, Aurigene’s team can provide wide various discovery and development services for multiple therapeutic modalities include antibodies, antibody-drug conjugates (ADCs), cell therapeutics, and viral vectors.
“We are delighted to add Edity to the growing list of global companies recognizing Aurigene as a valued partner in the biologics and advanced therapies space. Our true end-to-end service offering from discovery through large-scale cGMP [current good manufacturing practice] manufacture allows us to efficiently deliver speed, unwavering quality and economically viable solutions to our customers as they bring much-needed therapeutics to patients,” noted Dr. Roger Lias, global commercial head, biologics, Aurigene.
This deal is mutually beneficial for Edity, who expressed excitement at the opportunity to grow its pipeline.
“We are thrilled to be working with Aurigene's world-class team,” expressed Michal Golan Mashiach, CEO, Edity. “Their experience and breadth of technology offerings will help Edity to advance our pipeline and help patients with severe diseases. This collaboration will support our growth as we seek to create best-in-class medicines.”
In other biologics news, last month, Aurigene introduced its new 70,000 square-foot biologics facility in Genome Valley, which is located in Hyderabad, India.2 The plant is expected to help customers with process & analytical development, and small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. Currently, the process and analytical development laboratories are operational; however, the commissioning of manufacturing capacity will be completed later this year.
“There are very few global CDMOs that can truly support customers ‘end-to-end’ from discovery services to large scale commercial manufacture of both drug substance and drug product,” added Lias. “Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains and seek economically viable support for both their development portfolios and marketed products.”
References
1. Aurigene Pharmaceutical Services Limited, a global CRDMO, and Edity announce a strategic collaboration in cell therapy. Aurigene Pharmaceutical Services. Email PDF. July 1, 2024. Accessed July 2, 2024.
2. Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities. Aurigene Pharmaceutical Services Limited. June 3, 2024. Accessed July 2, 2024. https://www.aurigeneservices.com/sites/default/files/2024-06/Genomevalley-facility-press%20release-final-3rd-June-2024.pdf
